

Please replace the paragraph beginning at page 23, line 10, with the following rewritten paragraph:

--We turn now to the embodiment directed to a method of treating a patient in need of increased nitric oxide bioactivity, said method comprising administering to said patient a therapeutically effective amount of inhibitor of glutathione-dependent formaldehyde dehydrogenase. This embodiment may be referred to as the third embodiment herein.--

IN THE CLAIMS:

Please amend Claim 15 to be as follows:

15. (Amended.) A method for treating a patient in need of increased nitric oxide bioactivity, said method comprising administering to said patient a therapeutically effective amount of inhibitor of glutathione-dependent formaldehyde dehydrogenase.

Remarks

The specification has been amended at pages 3 and 23 and Claim 15 has been amended to recite that the treating agent is inhibitor of glutathione-dependent formaldehyde dehydrogenase rather than glutathione-dependent formaldehyde dehydrogenase.

That inhibitor of glutathione-dependent formaldehydes dehydrogenase is contemplated for the third embodiment is indicated in the application as filed at page 3, lines 3-5.

That inhibitor is meant as the treating agent for the third embodiment is indicated in the application as filed at page 24, lines 5-8 and page 24, lines 15-18 and at least by working Examples IV, V, X, XII and XIV.

Furthermore, Claim 20 as filed indicates that the treating agent for Claim 15 is inhibitor of glutathione-dependent formaldehyde dehydrogenase.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned **VERSION WITH MARKINGS TO SHOW CHANGES MADE**.

Please enter this amendment.

Respectfully submitted,

**JONES, TULLAR & COOPER, P.C.**

By:



Eric S. Spector  
Reg. No. 22,495

**JONES, TULLAR & COOPER, P.C.**  
P.O. Box 2266 Eads Station  
Arlington, Virginia 22202  
703-415-1500

Case Duke File No. 1838

Date: March 22, 2001



**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**IN THE SPECIFICATION:**

The paragraph beginning at line 15 of page 3 has been amended as follows:

Still another embodiment herein is directed to increasing NO bioactivity for pharmacological effect or in the case of diseases associated with a deficiency of NO. This embodiment is directed to a method of treating a patient in need of increased nitric oxide bioactivity, said method comprising administering to said patient a therapeutically effective amount of inhibitor of glutathione-dependent formaldehyde dehydrogenase.

The paragraph beginning at line 10 at page 23 has been amended as follows:

We turn now to the embodiment directed to a method of treating a patient in need of increased nitric oxide bioactivity, said method comprising administering to said patient a therapeutically effective amount of inhibitor of glutathione-dependent formaldehyde dehydrogenase. This embodiment may be referred to as the third embodiment herein.

**IN THE CLAIMS:**

Claim 15 has been amended as follows:

15. A method for treating a patient in need of increased nitric oxide bioactivity, said method comprising administering to said patient a therapeutically effective amount of inhibitor of glutathione-dependent formaldehyde dehydrogenase.